Literature DB >> 22258713

Quantitative volumetric analysis of gliomas with sequential MRI and ¹¹C-methionine PET assessment: patterns of integration in therapy planning.

Javier Arbizu1, S Tejada, J M Marti-Climent, R Diez-Valle, E Prieto, G Quincoces, C Vigil, M A Idoate, J L Zubieta, I Peñuelas, J A Richter.   

Abstract

PURPOSE: The aim of the study was to evaluate the volumetric integration patterns of standard MRI and (11)C-methionine positron emission tomography (PET) images in the surgery planning of gliomas and their relationship to the histological grade.
METHODS: We studied 23 patients with suspected or previously treated glioma who underwent preoperative (11)C-methionine PET because MRI was imprecise in defining the surgical target contour. Images were transferred to the treatment planning system, coregistered and fused (BrainLAB). Tumour delineation was performed by (11)C-methionine PET thresholding (vPET) and manual segmentation over MRI (vMRI). A 3-D volumetric study was conducted to evaluate the contribution of each modality to tumour target volume. All cases were surgically treated and histological classification was performed according to WHO grades. Additionally, several biopsy samples were taken according to the results derived either from PET or from MRI and analysed separately.
RESULTS: Fifteen patients had high-grade tumours [ten glioblastoma multiforme (GBM) and five anaplastic), whereas eight patients had low-grade tumours. Biopsies from areas with high (11)C-methionine uptake without correspondence in MRI showed tumour proliferation, including infiltrative zones, distinguishing them from dysplasia and radionecrosis. Two main PET/MRI integration patterns emerged after analysis of volumetric data: pattern vMRI-in-vPET (11/23) and pattern vPET-in-vMRI (9/23). Besides, a possible third pattern with differences in both directions (vMRI-diff-vPET) could also be observed (3/23). There was a statistically significant association between the tumour classification and integration patterns described above (p < 0.001, κ = 0.72). GBM was associated with pattern vMRI-in-vPET (9/10), low-grade with pattern vPET-in-vMRI (7/8) and anaplastic with pattern vMRI-diff-vPET (3/5).
CONCLUSION: The metabolically active tumour volume observed in (11)C-methionine PET differs from the volume of MRI by showing areas of infiltrative tumour and distinguishing from non-tumour lesions. Differences in (11)C-methionine PET/MRI integration patterns can be assigned to tumour grades according to the WHO classification. This finding may improve tumour delineation and therapy planning for gliomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258713     DOI: 10.1007/s00259-011-2049-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Use of fractional anisotropy for determination of the cut-off value in 11C-methionine positron emission tomography for glioma.

Authors:  Manabu Kinoshita; Naoya Hashimoto; Tetsu Goto; Takufumi Yanagisawa; Yoshiko Okita; Naoki Kagawa; Haruhiko Kishima; Hisashi Tanaka; Norihiko Fujita; Eku Shimosegawa; Jun Hatazawa; Toshiki Yoshimine
Journal:  Neuroimage       Date:  2008-12-10       Impact factor: 6.556

2.  How to use functional imaging information for radiotherapy planning.

Authors:  Anca-Ligia Grosu; Ursula Nestle; Wolfgang A Weber
Journal:  Eur J Cancer       Date:  2009-09       Impact factor: 9.162

3.  Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.

Authors:  June-Key Chung; Yu Kyeong Kim; Seok-ki Kim; Yong Jin Lee; Suntta Paek; Jeong Seok Yeo; Jae Min Jeong; Dong Soo Lee; Hee Won Jung; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-02       Impact factor: 9.236

4.  Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

Authors:  Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

5.  Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.

Authors:  Norbert Galldiks; Roland Ullrich; Michael Schroeter; Gereon R Fink; Andreas H Jacobs; Lutz W Kracht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

6.  Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience.

Authors:  Anca-Ligia Grosu; Rainer Lachner; Nicole Wiedenmann; Sibylle Stärk; Reinhard Thamm; Peter Kneschaurek; Markus Schwaiger; Michael Molls; Wolfgang A Weber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-08-01       Impact factor: 7.038

7.  Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients.

Authors:  Benoit J M Pirotte; Marc Levivier; Serge Goldman; Nicolas Massager; David Wikler; Olivier Dewitte; Michael Bruneau; Sandrine Rorive; Philippe David; Jacques Brotchi
Journal:  Neurosurgery       Date:  2009-03       Impact factor: 4.654

8.  Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.

Authors:  K Roessler; B Gatterbauer; A Becherer; M Paul; K Kletter; D Prayer; R Hoeftberger; J Hainfellner; S Asenbaum; E Knosp
Journal:  Minim Invasive Neurosurg       Date:  2007-10

9.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.

Authors:  Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

10.  WINPEPI (PEPI-for-Windows): computer programs for epidemiologists.

Authors:  Joseph H Abramson
Journal:  Epidemiol Perspect Innov       Date:  2004-12-17
View more
  26 in total

Review 1.  [Multiparametric imaging with simultaneous MRI/PET: Methodological aspects and possible clinical applications].

Authors:  S Gatidis; H Schmidt; C D Claussen; N F Schwenzer
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

Review 2.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

Review 3.  [Multiparametric imaging with simultaneous MR/PET. Methodological aspects and possible clinical applications].

Authors:  S Gatidis; H Schmidt; C D Claussen; N F Schwenzer
Journal:  Radiologe       Date:  2013-08       Impact factor: 0.635

Review 4.  The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint.

Authors:  Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

Review 5.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

Review 6.  'Low grade glioma': an update for radiologists.

Authors:  Jennifer Larsen; Steve B Wharton; Fiona McKevitt; Charles Romanowski; Caroline Bridgewater; Hesham Zaki; Nigel Hoggard
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

7.  Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI.

Authors:  Francesco Cicone; Christian P Filss; Giuseppe Minniti; Camilla Rossi-Espagnet; Annalisa Papa; Claudia Scaringi; Norbert Galldiks; Alessandro Bozzao; N Jon Shah; Francesco Scopinaro; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-07       Impact factor: 9.236

8.  Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients.

Authors:  Kentaro Kobayashi; Kenji Hirata; Shigeru Yamaguchi; Osamu Manabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Tohru Shiga; Naoya Hattori; Shinya Tanaka; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-08       Impact factor: 9.236

9.  Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates.

Authors:  David O Kamson; Csaba Juhász; Amy Buth; William J Kupsky; Geoffrey R Barger; Pulak K Chakraborty; Otto Muzik; Sandeep Mittal
Journal:  J Neurooncol       Date:  2013-01-09       Impact factor: 4.130

Review 10.  From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

Authors:  Norbert Galldiks; Karl-Josef Langen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-06-30       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.